Hepatitis B Virus
Sebivo (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Published in Hepatitis Weekly, May 14th, 2007
The European Commission today approved SEBIVO(R) (telbivudine), a new once-a-day oral treatment for adult patients with chronic hepatitis B (CHB) and evidence of viral replication and active liver disease. The European Commission decision applies to all 27 countries in the European Union as well as Iceland and Norway. Launches are expected to start in the second quarter of 2007 beginning with the United Kingdom and Germany. The approval of SEBIVO in Europe triggers a milestone payment from Novartis Pharma AG to Idenix. In addition to the European Union, SEBIVO is currently approved in more than 15 major markets, including the United States [where it is marketed as TYZEKA(R) (telbivudine)],...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-05-14)
More Articles from Hepatitis Weekly
- Hepatitis C Virus
Upping the Ante: Liver Center Leading Record Number of Studies to Attack Hepatitis C - Bird Flu
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals - Hepatitis
Research and Markets: US Based Bristol-Myers Squibb has Recently Introduced Baraclude to Meet the Rising, but as yet Unmet, Medical Need for Chronic Hepatitis B Treatment in India--India Pharmaceut - Hepatitis A Virus
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality - Hepatitis B Virus
DiaSorin Provides Hepatitis Training to Laboratory and Healthcare Workers - Hepatitis B Virus
Nucleonics Receives FDA Clearance to Begin Phase 1 Trial of Expressed RNAi Approach to Treating Chronic Hepatitis B Infections - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
